7 results on '"Şiraz, Ülkü Gül"'
Search Results
2. Clinical and Laboratory Characteristics of MODY Cases, Genetic Mutation Spectrum and Phenotype-genotype Relationship.
- Author
-
Özsu, Elif, Çetinkaya, Semra, Bolu, Semih, Hatipoğlu, Nihal, Erdeve, Şenay Savaş, Evliyaoğlu, Olcay, Baş, Firdevs, Çayır, Atilla, Dündar, İsmail, Akbaş, Emine Demet, Uçaktürk, Seyid Ahmet, Berberoğlu, Merih, Şıklar, Zeynep, Özalkak, Şervan, Şahin, Nursel Muratoğlu, Keskin, Melikşah, Şiraz, Ülkü Gül, Turan, Hande, Öztürk, Ayşe Pınar, and Mengen, Eda
- Subjects
METFORMIN ,MATURITY onset diabetes of the young ,TURKS ,HYPOGLYCEMIC agents ,ORAL drug administration ,DIABETIC acidosis ,DESCRIPTIVE statistics ,GENETIC variation ,HYPERGLYCEMIA ,GENETIC mutation ,INSULIN secretagogues ,DATA analysis software ,PHENOTYPES ,GENOTYPES ,GENETIC testing ,OBESITY ,CHILDREN - Abstract
Objective: Maturity onset diabetes of the young (MODY) occurs due to mutations in genes involved in pancreatic beta cell function and insulin secretion, has heterogeneous clinical and laboratory features, and account for 1-5% of all diabetes cases. The prevalence and distribution of MODY subtypes vary between countries. The aim of this study was to evaluate the clinical and laboratory characteristics, mutation distribution, and phenotype-genotype relationship in a large case series of pediatric Turkish patients genetically diagnosed with MODY. Methods: MODY cases from 14 different pediatric endocrinology departments were included. Diagnosis, treatment, follow-up data, and results of genetic analysis were evaluated. Results: A total of 224 patients were included, of whom 101 (45%) were female, and the mean age at diagnosis was 9.4±4.1 years. Gene variant distribution was: 146 (65%) GCK; 43 (19%) HNF1A; 8 (3.6%) HNF4A, 8 (3.6%) KLF11 and 7 (3.1%) HNF1B. The remaining 12 variants were: PDX (n=1), NEUROD1 (n=3), CEL (n=1), INS (n=3), ABCC8 (n= 3) and KJNC11 (n=1). Of the cases, 197 (87.9%) were diagnosed with incidental hyperglycemia, 16 with ketosis (7%) and 7 (3%) with diabetic ketoacidosis (DKA), while 30% presented with classical symptoms of diabetes. Two-hundred (89%) had a family history of diabetes. Anti-GAD antibody was detected in 13 cases, anti-islet antibody in eight and anti-insulin antibody in four. Obesity was present in 16. Distribution of therapy was: 158 (71%) diet only; 23 (11%) intensive insulin treatment; 17 (7.6%) sulfonylureas; 10 (4.5%) metformin; and 6 (2.7%) insulin and oral anti-diabetic treatment. Conclusion: This was the largest genetically diagnosed series from Turkey. The most common gene variants were GCK and HNF1A with much lower proportions for other MODY types. Hyperglycemia was the most common presenting symptom while 11% of patients had diabetes-associated autoantibodies and 7% were obese. The majority of patients received dietary management only. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. ROHHAD Syndrome, a Rare Cause of Hypothalamic Obesity: Report of Two Cases
- Author
-
Şiraz, Ülkü Gül, Ökdemir, Deniz, Direk, Gül, Akın, Leyla, Hatipoğlu, Nihal, Kendirci, Mustafa, and Kurtoğlu, Selim
- Subjects
endocrinological disorders ,ROHHAD syndrome ,Case Report ,Hypoventilation ,Syndrome ,Weight Gain ,Rare Diseases ,Autonomic Nervous System Diseases ,Child, Preschool ,Humans ,Female ,Obesity ,Child ,Hypothalamic Diseases ,hypothalamic dysfunction - Abstract
Rapid-onset obesity with hypoventilation, hypothalamic dysfunction and autonomic dysregulation (ROHHAD) syndrome is a rare disease that is difficult to diagnosis and distinguish from genetic obesity syndromes. The underlying causes of the disease have not been fully explained. Hypothalamic dysfunction causes endocrine problems, respiratory dysfunction and autonomic alterations. Currently there are around 80 reported patients although this is likely due to underdiagnosis due to lack of recognition. We present two female patients suspected of ROHHAD due to weight gain starting in early childhood. Clinical and biochemical findings such as respiratory and circulatory dysfunction, hypothalamic hypernatremia, central hypothyrodism, hyperprolactinemia and central early puberty in these patients matched the criteria for ROHHAD syndrome. ROHHAD syndrome should be considered in the differential diagnosis of monogenic obesity.
- Published
- 2018
4. The effect of the COVID-19 pandemic on metabolic control in children with type 1 diabetes: a single-center experience.
- Author
-
Sarıkaya, Emre, Çiçek, Dilek, Gök, Ebru, Kara, Leyla, Berber, Uğur, Şiraz, Ülkü Gül, Kendirci, Mustafa, and Hatipoğlu, Nihal
- Abstract
Coronavirus disease 2019 has caused a major epidemic worldwide, and lockdowns became necessary in all countries to prevent its spread. This study aimed to evaluate the effects of staying-at-home practices on the metabolic control of children and adolescents with type 1 diabetes during the pandemic period. Eighty-nine patients younger than 18 years old who were diagnosed with type 1 diabetes at least one year before the declaration of the pandemic were included in the study. The last visit data of the patients before and after the declaration of the pandemic, and the frequency of presentation of diabetes-related emergencies from one year after diagnosis of type 1 diabetes to the declaration of the pandemic, and from the declaration of the pandemic to the last visit after the pandemic declaration were compared. The total number of patients was 89, and 48 (53.9%) were boys. The mean (± standard deviation [SD]) age at diagnosis was 8.4 ± 3.7 years (boys 7.9 ± 3.6 years; girls 8.9 ± 3.9 years). There was no statistically significant difference when the SD values of the anthropometric measurements, and the glycosylated hemoglobin (HbA1c) and lipid profile tests were compared. However, the frequency of admission to the emergency service related to diabetes was significantly different. Although the pandemic did not significantly affect the metabolic and glycemic controls of the children with type 1 diabetes included in this study, an increase in the frequency of diabetes-related emergency admissions was noted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Can Fetuin-A Be a Marker for Insulin Resistance and Poor Glycemic Control in Children with Type 1 Diabetes Mellitus?
- Author
-
Şiraz, Ülkü Gül, Doğan, Murat, Hatipoğlu, Nihal, Muhtaroğlu, Sabahattin, and Kurtoğlu, Selim
- Subjects
- *
ADIPOSE tissues , *ANTHROPOMETRY , *BIOMARKERS , *BIOCHEMISTRY , *CHOLESTEROL , *FATTY liver , *GLYCOPROTEINS , *GLYCOSYLATED hemoglobin , *INSULIN resistance , *TYPE 1 diabetes , *PHENOMENOLOGY , *RELIABILITY (Personality trait) , *ULTRASONIC imaging , *EARLY diagnosis , *CAROTID intima-media thickness , *GLYCEMIC control , *DISEASE complications , *CHILDREN - Abstract
Objective: Metabolic impairment in type 1 diabetes mellitus (T1DM) with poor glycemic control causes insulin resistance, non-alcoholic fatty liver disease (NAFLD), atherosclerosis, and increased carotid intima-media thickness (CIMT). Fetuin-A has a protective effect in cardiovascular disorders and is increased in hepatosteatosis. We aimed to investigate the reliability of fetuin-A levels in early detection of diabetic complications in children with T1DM and to identify a cut-off value that may show poor metabolic control. Methods: The study included 80 patients who had T1DM for at least 5 years and who had no chronic complications or an auto-immune disorder. Blood samples were drawn to measure hemoglobin A1c (HbA1c), biochemical parameters, and fetuin-A levels. Anthropometric parameters were also measured. Percent body fat was calculated. Hepatosteatosis and CIMT were assessed by sonography. Results: Mean age of the patients was 13.5 years. Grade 1 hepatosteatosis was detected in 10%. Patients were stratified into 2 groups based on presence of NAFLD. Fetuin-A level was increased in patients with NAFLD. We identified a fetuin-A cut-off value (514.28 ng/mL; sensitivity: 47.34; specificity: 96.72) that may predict NAFLD. HbA1c and total cholesterol levels were found to be higher in patients with fetuin-A levels above higher the cut-off value. Conclusion: Fetuin-A is a reliable parameter in the prediction of complications and poor glycemic control in patients with T1DM. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Evaluation of Growth Characteristics and Final Heights of Cases Diagnosed with Noonan Syndrome on GH Treatment.
- Author
-
Şıklar Z, Berberoğlu M, Kızılcan Çetin S, Yıldız M, Turan S, Darcan Ş, Çetinkaya S, Hatipoğlu N, Yıldırım R, Demir K, Vermezoğlu Ö, Yavaş Abalı Z, Özalp Kızılay D, Görkem Erdoğan N, Şiraz ÜG, Orbak Z, Özgen İT, Bideci A, Selver Eklioğlu B, Karakılıç Özturan E, Tarçın G, Bereket A, and Darendeliler F
- Abstract
Introduction: Proportional short stature is one of the most important features of Noonan Syndrome, and adult height often remains below the 3rd percentile. Although the pathophysiology of short stature in NS patients is not fully understood, it has been shown that GH treatment is beneficial in NS, and it significantly improves the height in respect to the results of short and long-term GH treatment., Methods: In this study, the efficacy of GH therapy was evaluated in children and adolescents with Noonan syndrome who attained final height. In this national cohort study, 67 cases with NS who reached final height from 14 centers were evaluated., Results: A total of 53 cases (mean follow-up time 5.6 years) received GH treatment. Height SDS of the subjects who were started on GH tended to be shorter than those who did not receive GH (-3.26± 1.07 vs. -2.53 ±1.23) at initial presentation. The mean final height and final height SDS in girls using GH vs those not using GH were 150.1 cm and -2.17 SD vs 47.4 cm and-2.8 SD, respectively. The mean final height and final height SDS in boys using GH vs. not using GH were 162.48 ± 6.19 cm and -1.81 SD vs 157.46 ± 10.16 cm and -2.68 ± 1.42 SD, respectively. The Δheight SDS value of the cases was significantly higher in the group receiving GH than in those not receiving GH (1.36 ± 1.12 SD vs. -0.2 ± 1.24, p<0.001). Cardiac findings remained stable in two patients with hypertrophic cardiomyopathy who received GH treatment. No significant side effects were observed in the cases during follow-up., Conclusion: In patients with Noonan syndrome who reach their final height, a significant increase in height is observed with GH treatment, and an increase of approximately +1.4 SDS can be achieved. It has been concluded that GH treatment is safe and effective.
- Published
- 2024
- Full Text
- View/download PDF
7. The effect of the COVID-19 pandemic on metabolic control in children with type 1 diabetes: a single-center experience.
- Author
-
Sarıkaya E, Çiçek D, Gök E, Kara L, Berber U, Şiraz ÜG, Kendirci M, and Hatipoğlu N
- Subjects
- Adolescent, Age of Onset, Anthropometry, Body Weight, Child, Child, Preschool, Diabetes Complications epidemiology, Diabetes Mellitus, Type 1 diet therapy, Exercise Therapy, Female, Glycated Hemoglobin analysis, Humans, Lipids blood, Male, Patient Compliance, COVID-19, Diabetes Mellitus, Type 1 metabolism, Diabetes Mellitus, Type 1 therapy, Glycemic Control, Pandemics
- Abstract
Objectives: Coronavirus disease 2019 has caused a major epidemic worldwide, and lockdowns became necessary in all countries to prevent its spread. This study aimed to evaluate the effects of staying-at-home practices on the metabolic control of children and adolescents with type 1 diabetes during the pandemic period., Materials and Methods: Eighty-nine patients younger than 18 years old who were diagnosed with type 1 diabetes at least one year before the declaration of the pandemic were included in the study. The last visit data of the patients before and after the declaration of the pandemic, and the frequency of presentation of diabetes-related emergencies from one year after diagnosis of type 1 diabetes to the declaration of the pandemic, and from the declaration of the pandemic to the last visit after the pandemic declaration were compared., Results: The total number of patients was 89, and 48 (53.9%) were boys. The mean (± standard deviation [SD]) age at diagnosis was 8.4 ± 3.7 years (boys 7.9 ± 3.6 years; girls 8.9 ± 3.9 years). There was no statistically significant difference when the SD values of the anthropometric measurements, and the glycosylated hemoglobin (HbA1c) and lipid profile tests were compared. However, the frequency of admission to the emergency service related to diabetes was significantly different., Conclusions: Although the pandemic did not significantly affect the metabolic and glycemic controls of the children with type 1 diabetes included in this study, an increase in the frequency of diabetes-related emergency admissions was noted., (© 2021 Walter de Gruyter GmbH, Berlin/Boston.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.